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Apoptotic cells are rapidly phagocytosed and eliminated from the organism. Although
cancer cells apoptose when treated with anticancer drugs, how those cells are recognized by
phagocytic cells has remained unclear. The human leukemia cell line Jurkat was cultured
with doxorubicin or bufalin and induced to undergo apoptosis accompanied by phos-
phatidylserine externalization. When apoptotic Jurkat cells were mixed with mouse
peritoneal macrophages, efficient phagocytosis was observed. Apoptosis and phagocytosis
of Jurkat cells were both inhibited by Z-VAD-FMK, and phagocytosis was significantly
reduced in the presence of phosphatidylserine-containing liposomes. These results suggest
that anticancer drugs induce apoptosis-dependent and phosphatidylserine-mediated
phagocytosis in cancer cells.
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Apoptotic cells are engulfed by phagocytic cells, and this
event has been presumed to prevent damage to surrounding
tissues by the noxious contents of dead cells (reviewed in
Refs. 1, 2). Another important role of phagocytosis of
apoptotic cells has recently been proposed: that is, phago-
cytic cells present antigens, which apoptotic cells contain,
on their surface and stimulate T lymphocytes {3-7).
Furthermore, injection of macrophages that had phago-
cytosed apoptotic tumor cells led to tumor regression in
rats (7). These observations strongly suggest that apoptotic
cell phagocytosis occurs to eliminate unwanted cells not
only directly but also indirectly by activating the immune
response. It is important to elucidate the mechanism by
which phagocytic cells recognize and phagocytose apoptotic
cells in order to apply this phenomenon to the development
of novel therapeutics against cancer.
Phagocytes should distinguish target apoptosing cells
from living cells to selectively engulf the former. A variety
of molecules, such as proteins, sugars, and phospholipids,
have been suggested to act as a "phagocytosis marker,"
which is exposed on the surface of apoptotic cells and
recognized by phagocytes (reviewed in Refs. 8-10). Among
them, the membrane phospholipid PS has been most
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extensively characterized (reviewed in Ref. 11). In many
apoptosing cells, including lymphocytes {12), vascular
smooth muscle cells {13), vascular endothelial cells {14),
spermatogenic cells (25), and Fas-overexpressing HeLa
cells {16), externalized PS serves as a marker to allow
phagocytes to recognize target cells. Many anticancer drugs
induce apoptosis in cancer cells (reviewed in Refs. 17-19),
and this is often accompanied by PS externalization {20).
Apoptotic cells with externalized PS are, however, not
necessarily phagocytosed in the PS-mediated manner {21,
22). We investigated here how anticancer drug-treated
apoptotic cancer cells are phagocytosed by macrophages.
MATERIALS AND METHODS
Cell Culture and Apoptosis Analysis—Jurkat cells, a
human leukemia T-cell line, were grown in RPMI 1640
(Nissui Pharmaceutical, Tokyo) containing 10% fetal
bovine serum at 37'C in a humidified atmosphere with 5%
CO2 in air. The cells were treated with either doxorubicin
(Sigma, MO) (0.3 //g/ml) or bufalin (provided by K.
Nakaya) (10~7 M). Cell viability and chromatin condensa-
tion were analyzed under a microscope after staining cells
with trypan blue or Hoechst 33342, respectively. PS
externalization was determined by flow cytometry (EPICS-
XL; Coulter, FL) as described previously {23, 24). Briefly,
test cells were treated with FITC-labeled annexin V (Ben-
der MedSystems, Vienna, Austria) and propidium iodide,
and cells that were less intensely stained with propidium
iodide were gated and analyzed for the binding of FITC-
annexin V. For confirmation of cell surface binding of
FITC-annexin V, cells mixed with the fluorescent dyes
were further treated with trypan blue (2 mg/ml) at pH 4.5
prior to flow cytometry. Trypan blue, a plasma membrane
nonpermeable dye, binds to FITC and diminishes its
fluorescence because of energy transfer (quenching) {25).
To inhibit apoptosis, the caspase inhibitor Z-VAD-FMK
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(26) (Peptide Institute, Osaka) was added to cultures 1 h
before anticancer drug treatment.
Macrophage Preparation and Phagocytosis Assay—
Macrophages were prepared from peritoneal fluids of
thioglycollate-inoculated BDFi mice (female, 8 weeks old)
as described previously (16) and cultivated on cover slips
(15 mm diameter) in RPMI 1640 containing 10% fetal
bovine serum at 37"C until use. The phagocytosis assay was
performed essentially as described (25). Briefly, target
cells were labeled with biotin (NHS-LS-Biotin; Pierce,
Rockford, IL), mixed with macrophages (at a ratio of 10
target cells to one macrophage), and incubated at 37"C for
2-3 h. The mixture was treated with trypsin (0.5 mg/ml) to
remove Jurkat cells free from or lightly attaching to
macrophages. The remaining cells were further treated
with PBS containing paraformaldehyde (2%), glutaralde-
hyde (0.5%), and Triton X-100 (0.05%), then supplement-
ed with FITC-conjugated avidin (fluorescein-avidin D;
Vector Laboratories, Burlingame, CA). To analyze chro-
matin condensation and nuclear morphology of phago-
cytosed Jurkat cells, the fixed cells were further treated
with propidium iodide, which binds to DNA. The number of
macrophages containing engulfed cells was determined
under a fluorescence/phase-contrast microscope and ex-
pressed relative to that of total macrophages, Le., as the
phagocytic index. The mean and SD of a typical example
from at least three independent experiments are present-
ed. For liposome preparations, phospholipids (Avanti Polar
Lipids, Alabaster, AL) were dried as films, suspended in
PBS, and sonicated. The liposomes were composed of either
PC only (PC-liposomes) or a combination of PC and PS at a
molar ratio of 7:3 (PS-liposomes).
RESULTS
Apoptosis of Anticancer Drug-Treated Jurkat Cells—
We chose two apoptosis-inducing anticancer drugs, doxor-
ubicin and bufalin. The drugs possess distinct modes of
action: doxorubicin intercalates DNA and mainly affects
nucleic acid synthesis {27), while bufalin inhibits Na+,K+-
ATPase in the plasma membrane (28). Human leukemic
Jurkat cells were cultured in the presence of these drugs,
and cell viability and chromatin condensation were ex-
amined (Fig. 1A). Both drugs showed similar effects: cell
viability decreased (left panel) and the number of cells with
condensed chromatin increased (right panel) as the time of
drug treatment was prolonged. Chromatin condensation
caused by either drug was significantly inhibited in the
presence of a caspase inhibitor, Z-VAD-FMK (Fig. IB).
These results indicated that doxorubicin and bufalin induce
apoptosis in Jurkat cells.
We next examined whether this apoptosis is accom-
panied by PS externalization. To do so, drug-treated Jurkat
cells were stained with FITC-annexin V and propidium
iodide, and analyzed by flow cytometry. When the cells less
intensely stained with propidium iodide were examined for
the binding of FITC-annexin V, an extra peak with more
fluorescence appeared after treatment with either drug,
although the size of the peaks was different (left panels in
Fig. 2A). Such peaks completely disappeared when the cells
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Fig. 1. Anticancer drug-induced apopto-
sis of Jurkat cells. (A) Jurkat cells treated
with doxorubicin (DXB) or bufalin (BFL) for
the indicated periods were analyzed for cell
viability (trypan blue staining) (left) and
occurrence of apoptosis (chromatin condensa-
tion) (right). (B) Jurkat cells were incubated
with Z-VAD-FMK (20 or 40 //M) for 1 h prior
to the treatment with doxorubicin (left) or
bufalin (right), and the extent of apoptosis was
determined.
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Fig. 2. PS externalization in anticancer drug-treated Jurkat
cells. (A) Jurkat cells that had been treated with doxorubicin or
bufalin for 24 h were analyzed for PS externalization by flow cyto-
metry in the absence (—) or presence ( + ) of trypan blue. Cells less
intensely stained with propidium iodide (zone A in the left-most
panel) were analyzed for the binding of annexin V (histograms at the
right). The numbers indicate the percentages of cells in the corre-
sponding areas. (B) The same assay was conducted with cells that
were cultured in the presence of Z-VAD-FMK (20 or 40 ^ M).
were treated with trypan blue to quench fluorescence from
the cell surface (right panels), indicating that cells corre-
sponding to the extra peaks contained surface-bound FITC-
annexin V. Moreover, the addition of Z-VAD-FMK inhib-
ited the appearance of such peaks (Fig. 2B). From these
results, we concluded that PS, which is normally restricted
to the cytoplasmic side of living cells, was externalized and
exposed on the surface of apoptotic Jurkat cells upon
treatment with either doxorubicin or bufalin.
Phagocytosis of Anticancer Drug-Treated Jurkat Cells
by Mouse Peritoneal Macrophages—Jurkat cells that had
been cultured with the drugs for 24 h were labeled with
biotin and mixed with mouse peritoneal macrophages. The
mixture was incubated for 2-3 h, washed, permealized, and
supplemented with FITC-avidin. When the reacted cells
were examined under a fluorescence/phase-contrast micro-
scope, many fluorescent particles were detectable in the
cytoplasm of macrophages (Fig. 3A). Jurkat cells left
untreated with the drugs were not significantly engulfed by
macrophages (Fig. 3B). There was no significant difference
between the two drugs. When the macrophages that reacted
with doxorubicin-treated Jurkat cells were further stained
with propidium iodide, many phagocytosed Jurkat cells
whose nuclei were not intensely stained or fragmented
were observed (Fig. 3C). A similar result was obtained with
bufalin-treated Jurkat cells (data not shown). These results
indicated that macrophages phagocytosed drug-treated
Jurkat cells before their chromatin condensed and nuclei
were fragmented. Quantification of the phagocytosis reac-
tion revealed that Jurkat cells treated with either drug
became susceptible to phagocytosis by macrophages (Fig.
3D). Phagocytosis was significantly reduced when Jurkat
cells were treated with the anticancer drugs in the presence
of Z-VAD-FMK (Fig. 3E), indicating that phagocytosis was
dependent on apoptosis. The above results all showed that
Jurkat cells treated with either doxorubicin or bufalin were
phagocytosed by peritoneal macrophages at early stages of
apoptosis.
Involvement of PS in Phagocytosis of Anticancer Drug-
Treated Cells—Since externalized PS often serves as a
marker in phagocytosis of apoptotic cells {11), we next
asked if this is the case with anticancer drug-treated Jurkat
cells, by conducting the phagocytosis assay in the presence
of liposomes. Liposomes containing PS and PC significantly
inhibited phagocytosis of Jurkat cells treated with either
drug, whereas those composed of only PC showed a minimal
effect (Fig. 4). These results suggested that phagocytosis of
the drug-treated Jurkat cells by macrophages was mediat-
ed, at least partly, by PS exposed on the cell surface.
Significant levels of phagocytosis, however, always
occurred in the presence of a maximal amount of PS-lipo-
somes, suggesting the existence of PS-independent phago-
cytosis. We thus investigated the involvement of other
possible phagocytosis markers (Fig. 5). A synthetic peptide
containing the integrin-binding sequence RGDS; fucoidan
and dextran sulfate, specific inhibitors of class A scavenger
receptor types I and II; and N-acetyl-D-glucosamine, a
ligand for lectin-like receptors, all showed some inhibition,
but were much less effective than PS-liposomes. Further-
more, simultaneous addition of PS-liposomes and fucoidan
or dextran sulfate gave no additive effect. Similar results
were obtained in the phagocytosis assays of Jurkat cells
treated with either doxorubicin or bufalin. These results
suggest that as-yet unidentified molecules, in addition to
PS, are involved in the recognition by macrophages of
apoptotic Jurkat cells.
DISCUSSION
Although anticancer drugs induce apoptosis that is accom-
panied by externalization of PS in many cancer cell lines
(20), it has not yet been shown whether those cells undergo
PS-mediated phagocytosis. The present study showed that
macrophages phagocytosed Jurkat cells, which were under-
going apoptosis induced by treatment with either doxor-
ubicin or bufalin, in a manner inhibitable by PS-containing
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Fig. 3. Phagocytosis of antican-
cer drug-treated Jurkat cells by
mouse peritoneal macrophages.
(A) The mixture of Jurkat cells and
macrophages after the phagocytosis
reaction was examined under a fluo-
rescence/phase-contrast micro-
scope. Bar-10//m. (B) Jurkat cells
untreated with the drugs were sub-
jected to the phagocytosis assay. Bar
-50 nva. (C) Nuclear morphology of
engulfed Jurkat cells. Jurkat cells
treated with doxorubicin were sub-
jected to the phagocytosis assay
using FITC-avidin, and the reactive
cells were further stained with pro-
pidium iodide. Top left, FTTC signal
from the surface of phagocytosed
Jurkat cells; top right, propidium
iodide signal from DNA of macro-
phages and Jurkat cells; bottom left,
superimposition of the two signals;
bottom right, phase-contrast view.
Bar=50^m. (D) Quantification of
phagocytosis reactions. Columns and
bars are means + / - SD. (E) The
phagocytosis assay was conducted in
the presence of Z-VAD-FMK (40
//M). The extent of phagocytosis is
expressed relative to that of control
reactions, taken as 100. The means
of the phagocytic index in control
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liposomes. Since these two drugs inhibit the growth of
cancer cells in different ways, it is likely that anticancer
drugs induce PS-mediated phagocytosis of cancer cells
irrespective of their mode of action in cell growth inhibi-
tion.
PS exists predominantly in the inner leaflet of the plasma
membrane bilayer of living cells, and translocates to the
outer leaflet upon induction of apoptosis (reviewed in Refs.
29, 30). Our results showed that PS externalization and
phagocytosis were both inhibited in the presence of an
apoptosis inhibitor. Induction of apoptosis and phagocytosis
are thus attributed to the same actions of anticancer drugs,
at least for the drugs used in this study. Cell growth
inhibition and apoptosis induction by anticancer drugs
J. Biochem.
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Fig. 5. Effect of potent inhibitors on
phagocytosis of anticancer drug-treat-
ed Jurkat cells. Various substances were
added to the phagocytosis assay. The ex-
tent of phagocytosis is shown relative to
that with no added inhibitor, taken as 100.
The means of the phagocytic index in
control reactions were 17-30. RGDS, a
synthetic peptide containing the integrin-
binding sequence RGDS; GlcNAc, N-ace-
tyl-D-glucosamine; fucoidan and dextran
sulfate, ligands for class A scavenger
receptor; PS, PS-liposomes; PC, PC-lipo-
somes. In the bottom two panels, PS-lipo-
somes (0.5 mM), fucoidan (100//g/ml),
and dextran sulfate (100//g/ml) were
added either alone or in combination.
Significance was calculated using Stu-






























20 40 60 80 100
Relative phagocytosis
Fig. 4. Effect of liposomes on phagocytosis of anticancer drug-
treated Jurkat cells. Phagocytosis reactions were conducted in the
presence of PS- or PC-liposomes (0.5 or 1 mM). The extent of
phagocytosis is shown relative to that with no added liposomes, which
is taken as 100. The means of the phagocytic index in control reactions
were 22 (DXR) and 17 (BFL).
might be caused by their distinct activities (31). One could
thus modify and improve anticancer drugs simply by
removing the former activity, which might cause severe
side effects. Moreover, novel drugs may be discovered
through screening of chemical and natural products, focus-
ing on apoptosis-inducing activity.
We previously showed that macrophages phagocytose
cells that expose PS independently of apoptosis (16). in the
present study, drug-treated Jurkat cells were targeted by
macrophages before nuclear morphology changed. We
speculate that PS externalization by itself, not other
apoptotic changes, is sufficient for drug-treated cells to be
phagocytosed. It is thus important to elucidate the mecha-
nism by which PS is exposed to the cell surface upon
anticancer drug treatment. One suggested mechanism is
that changes in the amount and/or activity of enzymes
defining localization of the phospholipid lead to its external-
ization (30). Two enzymes called aminophospholipid trans-
locase (32) and scramblase (33) are believed to control the
movement of PS. Characterization of these enzymes is
essential for understanding how PS is externalized upon
apoptosis induction. Once the precise mechanism becomes
clear, novel anticancer drugs that induce cell-surface PS in
cancer cells could be developed.
Macrophages probably recognize PS on target cells by
using its specific receptor. Several proteins have been
identified as candidates for the PS receptor (14, 34-41, and
reviewed in Ref. 11). Among them, class B scavenger
receptor type I and lectin-like oxidized low density lipopro-
tein receptor (14) were shown to serve as phagocytosis-
inducing PS receptors in testicular Sertoli cells (40) and
vascular endotheh'al cells (41), respectively. Although the
macrophage PS receptor still remains to be identified, one
could modify the quantity and/or quality of such a receptor
so that macrophages would phagocytose cancer cells with
higher selectivity and efficiency. Further studies are need-
ed to understand how anticancer drug-treated cancer cells
are recognized and phagocytosed by phagocytic cells, and
such studies should provide us with new approaches for the
development of novel therapeutic agents against cancer.
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